Media OutReach
Sanofi sets Singapore Book of Records with the ‘Largest Mural of Magnetic Hands’ – a Public Pledge against Respiratory Syncytial Virus (RSV) in Nationwide Awareness Campaign
- Sanofi has achieved a new Singapore Book of Records milestone featuring more than 1,000 RSV awareness pledges.
- The Together Against RSV campaign unites families, healthcare partners and communities to spotlight the risks of RSV and its impact on all infants.
- Each magnetic hand symbolises a pledge of protection, creating an impactful visual reminder of the nation’s shared commitment to safeguarding young children’s health against RSV.
SINGAPORE – Media OutReach Newswire – 13 October 2025 – Sanofi has made history with a nationwide public health activation by clinching a spot in the Singapore Book of Records with the ‘Largest Mural of Magnetic Hands’, a public pledge against Respiratory Syncytial Virus (RSV) in its Together Against RSV campaign. The striking mural featured a total of over 1,000 hand pledges, each representing a parent, caregiver, or supporter who committed to raising awareness of Respiratory Syncytial Virus (RSV) – a common yet potentially serious virus – and protecting all infants from its risks.
Over the three-day event at Serangoon NEX, families, healthcare partners, and community members came together to symbolically place hand-shaped magnets on a panelled mural, with each hand carrying a personal pledge of commitment to learning about and fighting against RSV.
Zainab Sadat, Head of Vaccines, Sanofi Southeast Asia & India
“This record is more than just numbers; it is a symbol of unity and a testament to the collective power of Singaporean families, healthcare professionals, and communities coming together for a cause that truly matters. Through our ‘Together Against RSV’ campaign, we hope to spark ongoing conversations about RSV and empower parents with knowledge and preventive measures, including immunisation options, to protect their little ones. Together, we are building a future where every baby can breathe a little easier, and every family can rest a little more peacefully.”
The mural, measuring 2 meters tall by 5.1 meters wide, now serves as a striking visual reminder of the nation’s shared commitment to combating RSV. The event also complemented wider awareness initiatives, including collaborations with hospitals, parent communities, and an educational microsite (TogetherAgainstRSV.sg) in collaboration with the Singapore Paediatric Society, as part of Sanofi’s mission to empower parents with trusted information and preventive solutions.
Around the world, about two in three infants contract RSV before their first birthday1, making it the most common cause of lower respiratory tract infections, including bronchiolitis and pneumonia, in young children2. In Singapore, RSV is also a leading cause of infant hospitalisations, with the majority of cases occurring in otherwise healthy, full-term babies. Each year, an estimated 1,804 children under 29 months are hospitalised due to RSV-related illness3-7.
Hashtag: #Sanofi
The issuer is solely responsible for the content of this announcement.
About RSV
RSV is a highly contagious virus that can lead to serious respiratory illness for infants.2 It is a leading cause of hospitalisation in all infants, with most hospitalisations for RSV occurring in otherwise healthy infants born at term3-7. Two out of three infants are infected with RSV during their first year of life and almost all children are infected by their second birthday1. Globally, in 2019, there were approximately 33 million cases of acute lower respiratory infections leading to more than three million hospitalisations, and it was estimated that there were 26,300 in-hospital deaths of children younger than five years8. RSV-related direct medical costs, globally — including hospital, outpatient and follow-up care — were estimated at €4.82 billion in 20179.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
For more information, visit 
www.sanofi.com.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
References
- Walsh, EE. Respiratory Syncytial Virus Infection: An Illness for All Ages. Clinics in Chest Medicine. 2017;38(1):29-36.
- Karron A. Respiratory Syncytial Virus Vaccines and Monoclonal antibodies. Orenstein W, Offit P, Edwards KM, Plotkin S. Plotkin’s Vaccines, eighth edition: 998-1004. Elsevier 2023.
- Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5 Suppl):S127-S132. doi:10.1067/s00223476(03)00510-9.
- Zhou H, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54:1427–1436.
- Rha B, et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics. 2020;146:e20193611.
- Arriola CS, et al. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15. J Pediatric Infect Dis Soc. 2020;9:587-595
- Tam CC, et al. Burden and Cost of Hospitalization for Respiratory Syncytial Virus in Young Children, Singapore. Emerg Infect Dis. 2020 Jul;26(7):1489-1496
- Li Y, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022;399:92047–64.
- Zhang S, et al. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis. J Infect Dis. 2020;222(Suppl 7):S680-687.
MAT-SG-2500364-1.0-10/202
Media OutReach
TSquared Lab launches TSquared Health, an AI-driven longevity ecosystem, with the acquisition of Noviu Health
Dr. Hisham Badaruddin Appointed Chief Medical Officer as TSquared Health Integrates Medical, Biomarker, and AI Longevity Capabilities
SINGAPORE – Media OutReach Newswire – 17 December 2025 – TSquared Lab today announced the launch of TSquared Health, a new longevity-focused company designed to help individuals understand and improve their healthspan. By unifying advanced biomarker testing, wearable-derived insights, AI-supported clinical guidance, and targeted optimisation pathways, TSquared Health delivers a structured and continuous approach to preventive care and healthspan optimisation.
As part of the launch, TSquared Health has acquired the clinical operations of Noviu Health, a longevity-focused medical practice operating for more than two years. The clinical division now spans across two locations, an established clinic at Upper Paya Lebar Road and a new flagship TSquared Health clinic in Singapore’s Central Business District, expanding access to physician-led longevity services.
TSquared Health’s medical strategy will be overseen by Dr. Hisham Badaruddin, a longevity-focused physician who has led preventive health programmes across clinical and corporate settings. He brings deep experience in metabolic and hormonal health, as well as data-informed personalised medicine, strengthening TSquared Health’s commitment to medically rigorous, data-driven longevity care.
From Total Transformation to Lifelong Transformation
TSquared Lab is widely recognised for its Total Transformation Ecosystem, a science-backed framework unifying personal training, recovery, nutrition, and expert coaching into a structured, results-focused journey. With TSquared Health, the ecosystem now extends into medically supervised longevity and healthspan optimisation.
“TSquared Lab was built on the belief that people deserve results that stay with them,” said Afshan Thakkar, CEO and Founder of TSquared Lab. “TSquared Health is the evolution of that vision — taking our transformation philosophy and applying it to longevity. It is not only about how strong you are today, but how strong, sharp, and independent you will remain decades from now. Our goal is to democratise world-class longevity care by making it accessible, actionable, and continuous.”
With metabolic and lifestyle-driven conditions rising across the region, demand for proactive healthcare has never been higher. TSquared Health addresses this need by supporting early identification, prioritised interventions, and doctor-led optimisation before symptoms develop, empowering clients to take control of their long-term well-being.
The TSquared Integrated AI Longevity Ecosystem
The longevity space today is fragmented: most clinics provide basic biomarker insights with limited follow-through, leaving clients without a clear path forward. TSquared Health was designed to close this gap through a fully integrated, closed-loop ecosystem that aligns medical diagnostics with real-world execution. The ecosystem integrates:
- Physician-led Longevity Assessment – Comprehensive medical evaluation focused on metabolic, cardiovascular, hormonal, inflammatory, and cognitive health.
- Advanced Biomarker Panels – Two membership tiers, Signature and Elite panels including a deep baseline and a follow-up round, enabling measurement of meaningful biological change over time
- Wearable & Device Insights – Continuous inputs such as sleep, recovery, activity, and HRV incorporated into interpretation
- AI Insights Layer – transforming biological data into prioritised, actionable steps and continuous monitoring
- Personalised Optimisation Pathways: Integrated support across training, movement, nutrition, recovery, and clinical protocols to help clients implement and sustain improvements
Aligned with TSquared Health’s commitment to accessibility, the Signature and Elite Panels are priced to make high-quality preventive testing available to far more people.
By unifying these five key components into a single coordinated system, TSquared Health ensures clients receive clear guidance, precise priorities, and real-world support that drives measurable change.
Turning Data into Action: The TSquared Healthspan Intelligence Engine
At the centre of the ecosystem is the TSquared Healthspan Intelligence Engine, a proprietary AI system that transforms each client’s biomarker, wearable, and lifestyle data into a personalised healthspan score and a focused set of prioritised actions.
Trained with extensive longevity research, the engine highlights the key factors across metabolic, cardiovascular, hormonal, inflammatory, cognitive, and recovery pathways.
Every output is reviewed by an experienced longevity physician, ensuring insights are medically sound, contextualised, and actionable. Rather than pages of raw numbers, clients receive clear, structured guidance on their results and the steps to take next.
The intelligence engine is included with every Signature and Elite Membership.
TSquared Health’s Closed-Loop Longevity Model
Assess. Interpret. Optimise.
Most longevity programmes stop at the first two steps. TSquared Health is built around the third, turning insights into action to drive measurable, long-term health improvements.
Once priorities are identified, TSquared Health activates targeted clinical pathways across its integrated ecosystem, supporting outcomes in areas such as metabolic health, hormonal balance, inflammation control, cardiovascular and cognitive optimisation, and recovery restoration.
“TSquared Health represents a new frontier in proactive healthcare,” said Dr. Hisham Badaruddin, Chief Medical Officer. “By combining biomarker testing, structured interpretation, and real-world intervention under one ecosystem, we can meaningfully shift the trajectory of our clients’ long-term health.”
Hashtag: #TSquaredLab
The issuer is solely responsible for the content of this announcement.
About TSquared Lab
TSquared Lab is a Singapore-born fitness, health, nutrition, and longevity company building one of the most comprehensive transformation ecosystems in Asia. Its integrated platform includes TSquared Personal Training, TSquared Physio, TSquared Eats, and TSquared Health, combining science-based methodologies, personalised coaching, and clinical insights to help individuals build long-term strength, health, and vitality.
About Dr. Hisham Badaruddin, Chief Medical Officer, TSquared Health
Dr. Hisham Badaruddin is a board-certified medical doctor with more than 30 years of clinical experience spanning internal medicine, metabolic health, men’s health, and preventive care. He is recognised for integrating traditional clinical practice with advanced biomarker analytics, longitudinal health tracking, and evidence-based optimisation strategies.
Before joining TSquared Health, Dr. Hisham led multidisciplinary preventive-health programmes across diverse populations. His clinical philosophy emphasises early detection, personalised intervention, and long-term healthspan improvement.
Media OutReach
Prediction is the New Protection: Gartner® Acknowledged CyCraft as a Sample Vendor We Believe for Emerging AI Cyber Solutions
With AI reshaping cybersecurity landscapes, it is pivotal to adopt unified management that preemptively leverages and secures AI. Integrating AI into cybersecurity defense is one of the emerging trends to combat AI-enabled or affiliated risks. C-suite executives and IT leaders must transit from the traditional detect-and-respond model to an AI-informed, proactive security governance.
Unified Exposed Assets and Attack Surface Management
“The complexity of modern environments leads to fragmented data and isolated visibility. Unified exposure management enables holistic visibility through unified telemetry, enabling comprehensive attack surface visibility, accurate risk assessment and prioritization of remediation efforts.”
Gartner, Emerging Tech: AI Vendor Race: Unified Exposure Management Will Drive Displacement of Fragmented Point Solutions, 29 September 2025.
CyCraft External Attack Surface Management (EASM) automatically discovers potential external threats, correlates multiple intelligence and provides an overview of digital assets from the attacker’s perspective. Constantly discovering exposed credentials on surface web, dark web or public markets, this module mobilizes early warning and leakage tracing. Moreover, with the exclusively trained AI model, EASM offers mitigation and audit recommendations tailored to various compliance requirements.
AI-empowered Model Safety, Application Security and Posture Governance
“The emerging AI-enabled threat landscape demands more than just faster detection and response; it requires predictive threat intelligence combined with AI-driven analytics and preemptive action. AI and machine learning (ML) technologies must be used to anticipate attack paths and predict where an adversary is likely to strike to more effectively neutralize potential attacks before they begin.”
Gartner, Emerging Tech Impact Radar: Preemptive Cybersecurity, 7 October 2025.
LLM inherent and related risks are not virtual shadows but substantial threats that jeopardize everyday existence. Since GenAI or LLM outputs are difficult to control, the continuous verification of both input and output is the only way to ensure the validity of a solution.
Built on this logic, CyCraft’s XecGuard is an easily deployable Guardrail module, including cybersecurity, compliance and ethical Guardrails. Defending against Prompt Injection, Jailbreak and Prompt Extraction, XecGuard tackles AI-enabled threats without compromising its performance.
To assess your LLM safety range with quantifiable standards, CyCraft XecArena provides different attack scenarios to compare their performance. Users need to coax the LLM to break its System Prompt or leak confidential information. Join this multi-round testing on XecArena now!
CyCraft continues driving AI innovation in enterprise cybersecurity. In our opinion, this research momentum has further been witnessed by the reception of NeurIPS and EMNLP.
“We believe, being acknowledged in these influential Gartner reports validates our strategic vision and technological innovation,” said Dr. Benson Wu, CEO and Co-Founder of CyCraft Technology. “We’ve consistently invested in AI-driven, preemptive capabilities that enable organizations to stay ahead of invisible threats.”
Limited Evaluation Program
EASM Lite Experience
Evaluation Application
For organizations seeking full functionality, CyCraft is offering a limited evaluation program for 50 qualified enterprises. Participants will receive two External Exposure Analysis Reports, enabling security and governance teams to quantify external attack surface risks and establish data-driven priorities for remediation.
Reports
Gartner, Emerging Tech Impact Radar: Preemptive Cybersecurity, 7 October 2025.
Gartner, Emerging Tech: AI Vendor Race: Unified Exposure Management Will Drive Displacement of Fragmented Point Solutions, 29 September 2025.
Disclaimer
Hashtag: #CyCraft
https://www.cycraft.com/en
https://www.linkedin.com/company/cycraft
https://www.facebook.com/cycrafttechnology
The issuer is solely responsible for the content of this announcement.
About CyCraft
CyCraft is a leading AI cybersecurity company, dedicated to automating cybersecurity with AI technology. With a proven track record in government, finance, high-tech semiconductor, and other industries, and strong recognition from international institutions, CyCraft continues to build Asia’s most advanced AI Security Operations Center, fully committed to safeguarding enterprise digital resilience.
Media OutReach
Cheers to New Beginnings: Carlsberg Hong Kong Launches No & Low-Alcohol and Beyond Beer Series for Conscious Celebrations
Ringing in the New Year, the extended collection promotes moderation and conscious drinking throughout the festive season and beyond
HONG KONG SAR – Media OutReach Newswire – 16 December 2025 – Carlsberg Hong Kong is championing moderation and mindful drinking with the launch of its extended No & Low-Alcohol Range and Beyond Beer product collection to ring in the New Year. Available from January 2026, the perfectly timed launch coincides with the season of gathering and the upcoming Dry January. The collection offers a refreshing, flavourful alternative for those looking to drink more consciously without compromising on taste or experience.
At the heart of this collection is Carlsberg 0.0, the flagship product that sets the standard for mindful drinking. With No Alcohol, No Sugar, and Low Calories, Carlsberg 0.0 delivers all the taste without the compromise – perfect for those who want to celebrate responsibly while maintaining a balanced lifestyle. True to its tagline, “Alcohol Free; Not Flavor Free,” Carlsberg No & Low-Alcohol Range together with its Beyond Beer collection proves that great beer experiences don’t need alcohol to shine.
Carlsberg Hong Kong Toasts to Mindful Drinking Choices
Driven by increasing consumer demand for healthier and more inclusive drinking options, especially among younger generations, Carlsberg Hong Kong’s latest beverage series embraces the shift toward moderation. Whether it’s over a festive meal, after a workout, or out with friends, the No & Low-Alcohol Range and Beyond Beer products is designed to support all types of occasions.
The lineup features new additions to Carlsberg’s expanding No & Low-Alcohol product portfolio, including:
- Poretti Zero, recognised as the winner of Italy’s “Elected Product of the Year 2025” in the Non-Alcoholic Beer Category, known for its delicate and velvety body crafted from four varieties of hops.
- Erdinger Alkoholfrei, is a full-bodied alcohol-free beer (ABV <0.5%) filled with notes of spicy malt, caramel sweetness and a touch of fruity acidity.
These are accompanied by trusted favourites like Carlsberg 0.0 – crafted using a unique brewing process that gently removes alcohol through evaporation, preserving the full flavour and refreshing character of traditional beer – Young Master Zero, Young Master Another One, Tetley’s Original Bitter, and the newly rebranded Jolly Shandy Lemon.
This launch also marks the first Dry January since Carlsberg Hong Kong began its strategic partnership with Young Master Brewery, holding exclusive distribution rights for its full portfolio of beers and Ready-to-Drink (“RTD”) products in Hong Kong and Macau since September. With this collaboration, Carlsberg is bringing Young Master’s award-winning products to more consumers than ever before through its extensive distribution network.
Nathaniel Moxom, Managing Director of Carlsberg Hong Kong and Taiwan, said “We are proud to lead the way in promoting mindful drinking and expanding the choices available to our consumers. Through our No & Low-Alcohol Range and Beyond Beer portfolio, we aim to make moderation both accessible and enjoyable, perfectly in tune with today’s evolving lifestyle habits.”
Discover What’s Brewing Beyond Beer
Carlsberg Hong Kong is also introducing a new product category under Beyond Beer, all with purest flavours derived from quality ingredients. This includes a curated range of premium mixers and non-alcoholic beverages designed to elevate the drinking experience, whether enjoyed on their own or as part of creative mocktails. Highlights include:
- Sophisticated mixers from The London Essence Company ranging from Indian tonic water, soda water and a delicate ginger ale.
- HIGHERTHAN 0% Salted Lime Soda with Electrolytes from HIGHERTHAN by Young Master, a first-in-market beverage featuring classic Hong Kong salted lime flavour, with added electrolytes – reimagined for modern hydration and boost.
Exclusive Deals to Sip, Shop and Savour
Carlsberg Hong Kong is rolling out a series of consumer promotions both in retail and on-premises throughout January. Shoppers at major supermarkets like Wellcome, ParknShop, city’super, and HKTVmall can enjoy special pricing and gifts with purchase. Customers who purchase designated amount of Carlsberg 0.0 in selected stores or ECOM platforms will receive a complimentary branded shoe bag. A tasting booth at designated city’super will also offer samples of Carlsberg 0.0, Poretti 0.0 and Erdinger 0.0 for curious shoppers.
On foodpanda, the full No & Low-Alcohol Beer and Beyond Beer range will be featured from January lasting for 6 weeks, with alcohol-free selections featured prominently for easy discovery. Participating restaurant brands will offer special promotions and in-app pick-up discounts to make conscious drinking even more accessible.
Around 70 participating outlets will run a Loyalty Stamp Card Programme throughout January. Guests who collect four stamps – one for each purchase of a Carlsberg 0.0 bottle – can redeem an exclusive Carlsberg 0.0 shoe bag, available while supplies last.
Hashtag: #CarlsbergHongKong
The issuer is solely responsible for the content of this announcement.
About Carlsberg Hong Kong
Carlsberg has grown into one of the world’s leading brewery groups, boasting an extensive portfolio of beer and beverage brands across 150 markets and employing 37,000 staff globally. Carlsberg Brewery Hong Kong Limited offers a diverse range of beers, including Carlsberg, 1664, Somersby, and SKOL.
With a rich tradition spanning 178 years, Carlsberg is driven by a spirit of innovation, curiosity, and an unwavering commitment to progress. The company is dedicated to brewing for a better today and tomorrow, continuously striving to enhance its offerings and foster a sustainable future.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking7 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn